Maximizing Quality of Life From the Get-Go in Neuro-Oncology Care

Commentary
Video

Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.

The goal of preserving quality of life (QOL) and extending the lives of patients with brain tumors remains “front and center” in neuro-oncology care, according to Sylvia Kurz, MD, PhD.

Kurz, an associate professor of Neurology (Neuro-Oncology) as part of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center, spoke with CancerNetwork® about key considerations for optimizing QOL and mitigating treatment-related toxicities that may occur among patients who undergo therapy for high-grade gliomas and other brain cancers. She stated that toxicities such as bone marrow suppression or chemotherapy-associated liver toxicity are typically manageable with strategies including dose modifications and symptomatic care.

In the neuro-oncology field, Kurz stated that clinicians typically think about potential symptoms and focus on the quality of care from the get-go. Additionally, she emphasized that severe long-term complications were usually rare among patients who received treatment for brain tumors.

Transcript:

The guidepost in neuro-oncology care in general is to maximize quality of life at any given time point. At this point, for many of these illnesses, including the high-grade gliomas, we’re not going for a cure, but the goal is to extend life and preserve quality of life as much as we can. That should be front and center for any treatment decisions.

Treatment-related toxicities in today’s neuro-oncology medicine probably [include] bone marrow suppression, kidney or liver toxicity from various forms of chemotherapies, and then the immunotherapy-related [adverse] effects. They are generally well managed with dose modifications, holding cycles of treatments, or symptomatic measures or care. Another big point of treatment-related toxicities is radiation-associated toxicities, where we use a drug called bevacizumab [Avastin] to help patients feel better and improve neurological symptoms.

The key consideration here is to always think about symptoms in patients and focus on quality of care from the get-go. I would also say that this is typically accomplished, and patients do as well as they can. Long-term severe complications are relatively rare in our field.

Recent Videos
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.